The combination of PGE2 and Toll-like receptor agonists (TLRs) can be used as a new standard for DCs with the ability to secrete and migrate cytokines, namely, TLR-P DCs, which successfully induce the response of antigen-specific CD8 T cells to tumour-associated antigens and damage cross-presentation of protein antigens in human DCs and CD8 T cells in a dose-dependent manner [128]. The gene discussed is CD8A; the disease is neoplasm.